logo
Plus   Neg
Share
Email

CRISPR Reports Positive Top-Line Results From Phase 1 Trial Of CTX110 - Quick Facts

CRISPR Therapeutics (CRSP) reported positive top-line results from the ongoing phase 1 CARBON trial evaluating the safety and efficacy of CTX110, an allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. In the study, 50% complete response rate was achieved at three months in the Dose Level 3 cohort. Safety profile was acceptable at Dose Level 3 or below, the company said.

"We are highly encouraged by the data which demonstrate the promise of allogeneic therapies in treating hematological malignancies. We continue to enroll patients and look forward to additional data read-outs for this program as well as our other allogeneic CAR-T programs, CTX120 and CTX130, next year," said Samarth Kulkarni, CEO of CRISPR Therapeutics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT